El interés en corto de Anika Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Anika Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Anika Therapeutics (NASDAQ:ANIK) Bolsa, Informe de interés en corto

Anika Therapeutics

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Anika Therapeutics Inc

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $37 to $25.

News

Price Target

Analyst Ratings

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $25

WIIM

Anika Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock increased by 88.0% to $1.76 during Thursday's regular session. The company's market cap stands at $9.7 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock increased by 27.24% to $13.03. The market value of their outstanding shares is at $15.0 million. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) stock increased by 22.59% to $7.0. The market value of their outstanding shares is at $593.5 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) stock rose 22.32% to $2.68. The company's market cap stands at $77.3 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares moved upwards by 22.05% to $6.95. The company's market cap stands at $1.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 19.08% to $3.12. The market value of their outstanding shares is at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock decreased by 69.1% to $0.6 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) stock decreased by 28.39% to $17.68. The company's market cap stands at $257.8 million. The company's, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 24.95% to $0.07. The company's market cap stands at $3.8 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock declined by 24.2% to $3.64. The market value of their outstanding shares is at $39.1 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares fell 23.13% to $4.76. The company's market cap stands at $325.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock fell 21.34% to $3.17. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

AVTE

AVXL

BFRI

CALC

CMPS

MDXG

MTNB

VCNX

XCUR

12 Health Care Stocks Moving In Thursday's Intraday Session

The sale of the Company's Arthrosurface business to Phoenix Brio, Incorporated closed today, October 31, 2024. The Company received consideration of $10 million in the form of a ten year non-interest bearing promissory note for $7 million, and an estimated $3 million of additional consideration subject to the sales performance of Arthrosurface.

Asset Sales

Anika Closes Divestiture Of Its Arthrosurface Business And Intention To Divest Of Parcus Medical Business

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.01) by 2400 percent. The company reported quarterly sales of $38.75 million which missed the analyst consensus estimate of $42.08 million by 7.91 percent. This is a 6.54 percent decrease over sales of $41.47 million the same period last year.

Earnings

Earnings Misses

Anika Therapeutics Q3 2024 Adj EPS $(0.25) Misses $(0.01) Estimate, Sales $38.75M Miss $42.08M Estimate

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) will release its quarterly earnings report on Thursday, 2024-10-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Anika Therapeutics to report an earnings per share (EPS) of $-0.01.
Anticipation surrounds Anika Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Anika Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>-0.19</td>
<td>-0.26</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>0.09</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-11.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730315032_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/ANIK/earnings">To track all earnings releases for Anika Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Anika Therapeutics's Earnings Preview

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and maintains $37 price target.

Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target

Fiscal 2024 Guidance
Anika continues to expect that revenue for fiscal 2024 will be in the range of $168 to $173 million, representing growth of 1% to 4% compared to 2023.
&nbsp;
Revenue ranges by product family are:
<ul>
<li>OA Pain Management of $102 to $104 million, up 0% to 2%</li>
<li>Joint Preservation and Restoration of $58 to $60.5 million, up 6% to 10%</li>
<li>Non-Orthopedic of $8 to $8.5 million, down 14% to 19%</li>
</ul>

Guidance

Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.05 by 240 percent. This is a 45.16 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $41.920 million which missed the analyst consensus estimate of $42.099 million by 0.43 percent. This is a 5.38 percent decrease over sales of $44.302 million the same period last year.

Earnings Beats

Anika Therapeutics Q2 2024 Adj. EPS $0.17 Beats $0.05 Estimate, Sales $41.920M Miss $42.099M Estimate

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
Over 300 surgeries completed during the limited market release, highlighting the growing interest and commercial demand across a wide range of tendon repairs

Biotech

General

Anika Therapeutics Announces Full Market Release Of Integrity Implant System

In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Anika Therapeutics, presenting an average target of $30.0, a high estimate of $37.00, and a low estimate of $22.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1716998434_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Anika Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Anika Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Anika Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Anika Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Anika Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Anika Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Anika Therapeutics's Background</h2>
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
<h3>Anika Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Anika Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 6.85%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Anika Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Anika Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Anika Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -1.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Anika Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights

Stephens &amp; Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Equal-Weight and maintains $24 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $24 Price Target

Buybacks

Anika Authorizes $40M Share Repurchase Program

Anika Enters Into Cooperation Agreement With Caligan Partners; Appoints Joseph Capper And William Jellison To Board Of Directors

The Company expects adjusted EBITDA for 2024 to be&nbsp;$25&nbsp;to&nbsp;$30 million, up over&nbsp;75%&nbsp;at the midpoint, representing an adjusted EBITDA margin of at least&nbsp;15%, up over 600 basis points compared to 2023.&nbsp;

Anika Says Cost Reduction Initiatives Complete; Says On-Track For FY24 Revenue Guidance Of $168M-$173M (Est $170.272M)

<a href="https://www.globenewswire.com/Tracker?data=EX0F8URG_wyMqlsm-sWNxBJ7v3RBFmDG6UWQyWPRH7KoWBGV7qSBx0aQI9pdZ8YhNTQtQovwDnpsBXKytLNOQWxNA5DTBRCtCQz9uI6KYsk=">Anika Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. &nbsp;
"We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve is an accomplished public company leader whose ability to connect strategic, operational, and financial expertise will be a significant asset for our Company. I am confident that Steve will build on our recent momentum and partner with our operating teams to achieve the meaningful value building potential across the business."
Dr. Blanchard continued, "On behalf of the Anika team, I'd like to thank Mike for his leadership over the past four years. Mike joined Anika in mid-2020 following our two acquisitions. His strategic and operational insights have helped Anika navigate this period of significant change while positioning the Company for an exciting future driven by thoughtful investments in Anika's market-leading hyaluronic acid business and key product developments in the highest opportunity spaces of orthopedics. We are glad to continue benefitting from his expertise through the end of this year and wish him the best."
"Joining Anika represents an exciting opportunity to contribute to a well-established, market-leading organization with a strong track record of developing innovative solutions in the highest opportunity spaces in orthopedics," said Mr. Griffin. "I look forward to partnering with Cheryl and the talented Anika team to unlock new opportunities with its significant pipeline of differentiated product lines to deliver sustainable, profitable growth."
"I'm very thankful for the opportunity to have been a part of the Anika team," said Mr. Levitz. "The Company has navigated a challenging period and made meaningful strides, including thoughtful investments as well as targeted cost reductions that together have strengthened its core OA business, advanced a meaningful portfolio and pipeline of differentiated products leveraging Anika's HA expertise, and maintained a healthy financial position. I am confident this progress will continue with Steve guiding our talented team and look forward to following Anika's success for years to come."

Management

Anika Announces Steve Griffin Appointed To CFO, Effective June 3, 2024

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.19) by 147.37 percent. The company reported quarterly sales of $40.523 million which beat the analyst consensus estimate of $39.143 million by 3.53 percent. This is a 6.85 percent increase over sales of $37.924 million the same period last year.

Anika Therapeutics Q1 2024 Adj EPS $0.09 Beats $(0.19) Estimate, Sales $40.523M Beat $39.143M Estimate

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and raises the price target from $29 to $37.

Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37

Anika Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation

The healthcare industry is growing massively owing to new drugs and technological innovations. Thus, investing in fundamentally robust small-cap stocks Theratechnologies (THTX), Anika Therapeutics. (ANIK), and SIGA Technologies (SIGA) could be a good idea. Read more to find out… The healthcare industry plays a major economic role by providing essential products and services that enhance people's health and well-being. Recent years have brought significant changes to the sector, driven by technological advancements, personalized healthcare, and biotechnological innovations.
Amid this, it could be wise to invest in fundamentally sound small-cap healthcare stocks Theratechnologies (<a href="https://stocknews.com/stock/THTX/">THTX</a>), Anika Therapeutics (<a href="https://stocknews.com/stock/ANIK/">ANIK</a>), and SIGA Technologies (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>). With a market capitalization of <a href="https://www.investopedia.com/terms/s/small-cap.asp">up to $2 billion</a>, these companies offer greater growth potential than large-cap firms and could be valuable additions to one's portfolio.
Over the last decade, significant advancements in survival rates and patient quality of life have greatly benefited the healthcare industry. These improvements stem from the intersection of medical and technological breakthroughs, which have enhanced the effectiveness of healthcare delivery and treatment outcomes.
Integrating high-tech diagnostic and therapeutic equipment with clinical practices has significantly improved healthcare outcomes. Innovations such as telemedicine, robotic process automation, and remote patient monitoring are <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10993086/">transforming patient care</a> by making it more efficient and accessible, benefiting the sector.
The continuous introduction of new drugs also benefits the industry by expanding treatment options and improving patient care. The U.S. Food and Drug Administration's <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approval of 23 new drugs</a> this year for various chronic conditions illustrates the sector's growth potential and capacity to advance medical treatments.
According to a report by Precedence Research, the global biotechnology market is expected to grow at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size%20was%20valued%20at,a%20CAGR%20of%2011.90%25%20from%202024%20to%202033.">a CAGR of 11.8%</a>, reaching approximately $4.25 trillion by 2033. This growth signifies increased investment and innovation, driving further advancements and improvements in patient care.
Considering these factors, let's explore the fundamentals of three promising small-cap healthcare stocks, starting with #3.
Stock #3: Theratechnologies Inc. (<a href="https://stocknews.com/stock/THTX/">THTX</a>)
THTX, based in Montreal, Canada, has a market capitalization of $62.76 million and develops therapies that address unmet medical needs. Its pipeline includes the F8 Formulation in Phase 2b/3 trials for tesamorelin in treating nonalcoholic steatohepatitis, a multi-dose pen injector for tesamorelin administration, and more.
On May 23, THTX reported <a href="https://www.theratech.com/news-releases/news-release-details/theratechnologies-sudocetaxel-zendusortide-asco-2024">Phase 1 data</a> for its investigational peptide drug conjugate, sudocetaxel zendusortide (TH1902). The data showcased promising long-term efficacy and a manageable safety profile in patients with solid tumors, highlighting the potential of TH1902 in advancing cancer treatment.
This could position THTX favorably for future development stages and regulatory approval.
On April 8, THTX showcased preclinical data <a href="https://www.theratech.com/news-releases/news-release-details/theratechnologies-preclinical-data-presentation-aacr-2024">demonstrating the versatility</a> of its SORT1+ Technology&#x2122; platform. The data revealed that camptothecin-peptide conjugates effectively regress tumors in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) models.
The validation could boost THTX's growth by confirming the platform's broad application and efficacy. The promising results could attract potential partners and investors, positioning THTX as a leader in innovative cancer treatments and accelerating its path to clinical development and market success.
For the fiscal 2024 second quarter that ended May 31, 2024, THTX reported revenue of $22.02 million, indicating a 25.5% year-over-year increase. Its profit from operating activities was $3.29 million compared to a loss of $7.94 million in the previous year's quarter.
Moreover, the company reported a <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and income per share of $987 thousand and $0.02, compared to a loss and loss per share of $10.01 million and $0.41 in the prior year's period.
Street expects THTX's revenue to rise 15.2% year-over-year to $23.94 million in the fiscal 2024 third quarter ending in August. The company's EPS is expected to be $0.04. Moreover, THTX has surpassed the consensus EPS estimates in three of the four trailing quarters.
Shares of THTX have gained 8.3% over the past three months and 1.11% over the past nine months to close the last trading session at $1.37.
THTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated considering 118 different factors, each weighted optimally.
THTX stock has an A grade for Growth and a B for Value and Sentiment. It is ranked #27 in the 639-stock <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
Beyond what is stated above, we've also rated THTX for Quality, Momentum, and Stability. <a href="https://stocknews.com/stock/THTX/">Click here</a> to get all THTX ratings.
Stock #2: Anika Therapeutics, Inc. (<a href="https://stocknews.com/stock/ANIK/">ANIK</a>)
Valued at $374.21 million, ANIK is a joint preservation company that develops and markets products using hyaluronic acid technology. Its product family includes Monovisc and Orthovisc for pain management, joint preservation solutions like Integrity and Hyalofast, Arthrosurface for sports medicine, and non-orthopedic products like adhesion barrier and wound care.
On July 11, ANIK announced <a href="https://ir.anika.com/Anika-Announces-Full-Market-Release-of-the-Integrity-TM-Implant-System,-a-Regenerative-Hyaluronic-Acid-Based-Scaffold-for-Rotator-Cuff-and-Other-Tendon-Repairs">a full market release</a> of its Integrity Implant System across the United States. The Integrity System includes a hyaluronic acid-based implant with bone and tendon fixation components and ingenious one-time use arthroscopic delivery instruments and is made to protect an injured tendon and propagate healing in rotator cuff repair and other tendon procedures
The positive feedback from the limited release underscores Integrity's clear advantages over collagen patches. Initially focused on rotator cuff repairs, Integrity's versatility has been proven in diverse applications, including Achilles tendon and foot repairs. This breakthrough positions ANIK as a leader in advancing surgical outcomes, driving its growth and reputation.
For the fiscal 2024 second quarter, which ended June 30, 2024, ANIK reported revenue of $41.92 million. The company's adjusted gross profit amounted to $27.52 million, while it registered an adjusted EBITDA of $6.29 million, indicating a marginal year-over-year increase.
Furthermore, ANIK's income from operations amounted to $161 thousand compared to a loss of $3.63 million in the previous year's quarter.
Analysts predict ANIK's revenue for the fiscal fourth quarter ending December 2024 to increase 5.8% year-over-year to $45.45 million. Its EPS for the same quarter is expected to grow 530% from the prior year's quarter to $0.32.  Moreover, the company surpassed consensus revenue estimates in all four trailing quarters.
The stock has gained 7.2% over the past six months and 20% over the past nine months to close the last trading session at $25.29.
ANIK's robust fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
ANIK has a B Growth and Stability. It is ranked #23 out of 639 stocks in the Biotech industry.
In addition to the POWR Ratings we've stated above, we also have ANIK ratings for Momentum, Value, Sentiment, and Quality. Get all ANIK ratings <a href="https://stocknews.com/stock/ANIK/">here</a>.
Stock #1: SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
With a market capitalization of $854.29 million, SIGA is a commercial-stage pharmaceutical firm focused on health security, including countermeasures for biological, chemical, radiological, and nuclear threats. Its lead product, TPOXX, is an antiviral drug available in oral and IV forms for treating human smallpox disease.
On July 19, SIGA announced that the U.S. Department of Health and Human Services had exercised <a href="https://investor.siga.com/investors/news/news-details/2024/SIGA-Announces-U.S.-Government-Procurement-Order-of-113-Million-for-Oral-TPOXX/default.aspx">a $113 million procurement option</a> for oral TPOXX&#xAE; treatment courses. The substantial order builds on 2023's orders from the U.S. government and 15 international customers.
The consistent support from government and international customers could enhance SIGA's market position and credibility, paving the way for continued innovation and readiness against biological threats.
On June 17, SIGA announced an agreement to <a href="https://investor.siga.com/investors/news/news-details/2024/SIGA-Announces-Agreement-to-Sell-TPOXX-to-ASEAN-Member-States-06-17-2024/default.aspx">expand access to TPOXX (tecovirimat)</a> across the ASEAN member states, a political and economic union in Southeast Asia. The agreement would help SIGA establish a presence in a densely populated area and lay the foundation for future developments.
SIGA's total revenue for the fiscal 2024 second quarter, which ended June 30, 2024, amounted to $21.81 million, showing a 270.9% year-over-year growth. The company's net income and EPS were $1.83 million or $0,03 per share, compared to a loss of $2.87 million and $0.04 in the previous year's quarter.
SIGA's revenue and EPS for the fiscal year ending December 2024 are expected to increase 14.7% and 6.3% year-over-year to $160.46 million and $1.01, respectively.
The stock has gained 52.5% over the past three months and 142.3% over the past nine months to close the last trading session at $11.97.
SIGA's positive fundamentals are mirrored in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
SIGA has an A grade for Value and Quality and a B for Growth. It is ranked #14 out of 362 stocks in the Biotech industry.
Beyond what we stated above, we also have given SIGA grades for Momentum, Stability, and Sentiment. Get all the SIGA ratings <a href="https://stocknews.com/stock/SIGA/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;

<hr />
SIGA shares fell $11.97 (-100.00%) in premarket trading Thursday. Year-to-date, SIGA has gained 113.75%, versus a 15.12% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/siga-anik-thtx-3-small-cap-healthcare-stocks-with-breakthrough-potential/>3 Small-Cap Healthcare Stocks With Breakthrough Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Healthcare Stocks With Breakthrough Potential

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chromadex (CDXC – Research Report) and Anika Therape...

Analysts Are Bullish on Top Healthcare Stocks: Chromadex (CDXC), Anika Therapeutics (ANIK)

Reports Q3 revenue $38.8M vs $41.465M last year. Cheryl R. Blanchard, Ph.D., Anika's President and CEO commented "OA Pain Management remains a stro...

Anika Therapeutics reports Q3 adjusted EPS (25c) vs 23c last year

Anika Therapeutics Non-GAAP EPS of -$0.25, revenue of $38.8M

Barrington analyst Michael Petusky maintained a Buy rating on Anika Therapeutics (ANIK – Research Report) today and set a price target of $25.00. M...

Optimistic Buy Rating for Anika Therapeutics Amidst Recent Setbacks and Strategic Growth Prospects

Barrington analyst Michael Petusky lowered the firm's price target on Anika Therapeutics (ANIK) to $25 from $37 and keeps an Outperform rating on t...

Anika Therapeutics price target lowered to $25 from $37 at Barrington

Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) has disclosed a new risk, in the Economy & Political Environment category. Anika Therapeutics, Inc. faces significa...

Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts

CDXC

SIGA

THTX

Press Releases

Anika Reports Second Quarter 2024 Financial Results

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Politan Provides Update on Why Masimo Shareholders Should Support Urgently Needed Board Change at Company's 2024 AGM

Anika Announces Third Quarter 2024 Results Conference Call Date

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

Anika Reports Third Quarter 2024 Financial Results

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Anika To Participate in December 2024 Investor Conferences

AVNT

MASI

MTRN

NOVT

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Anika Therapeutics

Interés en corto

Anika Therapeutics (NASDAQ:ANIK) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL